Document:

FORM OF RESTRICTED STOCK AWARD AGREEMENT

 Exhibit 10.9 
 RESTRICTED STOCK AWARD AGREEMENT 
 UNDER THE ELIXIR PHARMACEUTICALS, INC. 
 2007 STOCK OPTION AND INCENTIVE PLAN 
 Name of Grantee:
___________________________________ 
 No. of Shares: ______________________________________ 
 Grant Date: ________________________________________ 
 Final Acceptance Date: _______________________________ 
 Pursuant to the Elixir Pharmaceuticals, Inc. 2007 Stock Option and Incentive Plan (the “Plan”) as amended through the date hereof, Elixir
Pharmaceuticals, Inc. (the “Company”) hereby grants a Restricted Stock Award (an “Award”) to the Grantee named above. Upon acceptance of this Award, the Grantee shall receive the number of shares of Common Stock, par value $0.001
per share (the “Stock”) of the Company specified above, subject to the restrictions and conditions set forth herein and in the Plan. The Company acknowledges the receipt from the Grantee of consideration with respect to the par value of
the Stock in the form of cash, past or future services rendered to the Company by the Grantee or such other form of consideration as is acceptable to the Administrator. 
 1. Acceptance of Award. The Grantee shall have no rights with respect to this Award unless he or she shall have accepted this Award prior to the close of business on the Final Acceptance Date specified above by
(i) signing and delivering to the Company a copy of this Award Agreement, and (ii) delivering to the Company a stock power endorsed in blank. Upon acceptance of this Award by the Grantee, the shares of Restricted Stock so accepted shall be
issued and held by the Company’s transfer agent in book entry form, and the Grantee’s name shall be entered as the stockholder of record on the books of the Company. Thereupon, the Grantee shall have all the rights of a stockholder with
respect to such shares, including voting and dividend rights, subject, however, to the restrictions and conditions specified in Paragraph 2 below. 
 2. Restrictions and Conditions. 
 (a) Any book entries for the shares of Restricted
Stock granted herein shall bear an appropriate legend, as determined by the Administrator in its sole discretion, to the effect that such shares are subject to restrictions as set forth herein and in the Plan. 
 (b) Shares of Restricted Stock granted herein may not be sold, assigned, transferred, pledged or otherwise encumbered or disposed of by
the Grantee prior to vesting. 
 (c) If the Grantee’s employment with the Company and its Subsidiaries is voluntarily or
involuntarily terminated for any reason (including death) prior to vesting of shares of Restricted Stock granted herein, all shares of Restricted Stock shall immediately and automatically be forfeited and returned to the Company. 

 3. Vesting of Restricted Stock. The restrictions and conditions in Paragraph 2 of this
Agreement shall lapse on the Vesting Date or Dates specified in the following schedule so long as the Grantee remains an employee of the Company or a Subsidiary on such Dates. If a series of Vesting Dates is specified, then the restrictions and
conditions in Paragraph 2 shall lapse only with respect to the number of shares of Restricted Stock specified as vested on such date. 
  

					
	 Number of
Shares
Vested
	  	 Vesting Date

			
	 _____________
	 	(___%)	  	_____________
			
	 _____________
	 	(___%)	  	_____________
			
	 _____________
	 	(___%)	  	_____________
			
	 _____________
	 	(___%)	  	_____________
			
	 _____________
	 	(___%)	  	_____________

 Subsequent to such Vesting Date or Dates, the shares of Stock on which all restrictions and
conditions have lapsed shall no longer be deemed Restricted Stock. The Administrator may at any time accelerate the vesting schedule specified in this Paragraph 3. 
 4. Dividends. Dividends on Shares of Restricted Stock shall be paid currently to the Grantee. 
 5.
Incorporation of Plan. Notwithstanding anything herein to the contrary, this Agreement shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section 2(b) of
the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein. 
 6. Transferability. This Agreement is personal to the Grantee, is non-assignable and is not transferable in any manner, by operation of law or otherwise, other than by will or the laws of descent and distribution. 
 7. Tax Withholding. The Grantee shall, not later than the date as of which the receipt of this Award becomes a taxable event for Federal income
tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state, and local taxes required by law to be withheld on account of such taxable event. Except in the case where an election is made
pursuant to Paragraph 8 below, the Grantee may elect to have the required minimum tax withholding obligation satisfied, in whole or in part, by authorizing the Company to withhold from shares of Stock to be issued or released by the transfer agent a
number of shares of Stock with an aggregate Fair Market Value that would satisfy the withholding amount due. 
  

 2 

 8. Election Under Section 83(b). The Grantee and the Company hereby agree that the Grantee
may, within 30 days following the acceptance of this Award as provided in Paragraph 1 hereof, file with the Internal Revenue Service and the Company an election under Section 83(b) of the Internal Revenue Code. In the event the Grantee makes
such an election, he or she agrees to provide a copy of the election to the Company. 
 9. No Obligation to Continue Employment.
Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or this Agreement to continue the Grantee in employment and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or any
Subsidiary to terminate the employment of the Grantee at any time. 
 10. Notices. Notices hereunder shall be mailed or delivered to
the Company at its principal place of business and shall be mailed or delivered to the Grantee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing.

 [Remainder of Page Intentionally Left Blank.] 
  

 3 

			
	ELIXIR PHARMACEUTICALS, INC.
		
	By:	 	 
		 	Title:

 The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the
undersigned. 
  

					
			
	Dated: ____________________	 		 	  
		 		 	Grantee’s Signature
			
		 		 	Grantee’s name and address:
			
		 		 	 
			
		 		 	 
			
		 		 	 

  

 4EMPLOYMENT LETTER AGREEMENT WITH WILLIAM K. HEIDEN

 Exhibit 10.11 
 December 17, 2007 
 William K. Heiden 
 10
Livingston Road 
 Wellesley, MA 02482 
 Dear Mr. Heiden:

 Reference is made to that letter from Elixir Pharmaceuticals, Inc. (“Elixir” or the “Company”) to you, dated as of
September 2, 2004, in which Elixir offered you the full-time position of President and Chief Executive Officer (“Prior Letter Agreement”). As you are aware, Elixir has filed a registration statement with the Securities and Exchange
Commission for an initial public offering (“IPO”). In anticipation of our becoming a public company, Elixir is pleased to offer you the opportunity to amend and restate the terms of your employment agreement with Elixir, as set forth
below. If you accept this offer, this letter agreement will supersede the Prior Letter Agreement in its entirety. 
 In addition to the terms
set forth below, if you accept this offer I will recommend that Elixir’s Board of Directors (the “Board”) approve a stock option grant to you for the purchase of 100,000 shares of Elixir’s common stock (such number not to be
adjusted as a result of the reverse stock split contemplated in connection with the IPO) upon the effectiveness of the registration statement for the IPO at an option price per share equal to the price at which Elixir’s shares are offered to
the public in the IPO. 
 1. Your base salary will be at the rate of $13,520.00 per bi-weekly payroll period ($351,520 annually), in
accordance with Elixir’s regular payroll practices. All salary and other payments relating to your employment will be reduced by taxes and other amounts that Elixir is legally required to withhold or that you have authorized Elixir to withhold.

 2. Your base salary includes the cost of your participation in the Company’s long and short term disability insurance programs. The
premiums for this insurance will be deducted from your bi-weekly payroll payments on an after tax basis. This treatment is necessary to provide you with an after tax benefit should you receive benefits under either of the disability programs in the
future. 
 3. During your employment, you will be expected to devote your full business time and best professional efforts to the performance
of your duties and responsibilities for Elixir. As an Elixir employee you will perform duties assigned to you; comply with directions given to you; perform your job duties in accordance with Elixir’s policies; abide by all laws and regulations
that govern your employment; and use your best efforts to promote the interests of Elixir. You will be eligible for a performance and salary review during the first quarter of 2008. 

 Letter to William K. Heiden 
 Dated December 17, 2007 
 2 of 6 
  

 4. During your employment you will be eligible to participate in all benefit plans, provided you are
eligible, offered by Elixir to employees generally, subject to plan terms, applicable Elixir policies, and any required employee contributions. Benefits may be changed or terminated and new benefits may be added. 
 5. Your initial annual bonus target will be 75% of your base salary through September 8, 2007 and 50% thereafter. The actual amount of your annual
bonus award will be based upon on achievement of Company goals as well as your individual goals as determined by the Board or a committee thereof. Your bonus will be paid on the date annual bonuses are paid to other employees provided you remain
employed by Elixir at such time. The Board’s or its committee’s assessment of the Company’s and your prior year’s performance will be made during the first calendar quarter of the following year. 
 6. In connection with your employment, you executed an Employee Non-Disclosure and Developments Agreement and a Non-Competition and Non-Solicitation
Agreement, copies of which are attached to this letter agreement (“Restrictive Covenants”). You hereby represent that you have fully complied with the terms of the Restrictive Covenants. Your further acknowledge and agree that the
Restrictive Covenants shall remain in full force and effect and are hereby incorporated by reference into this letter agreement. In the event you receive Severance Benefits (as defined below) pursuant to this letter agreement and you fail to comply
with any Restrictive Covenant obligation, in addition to any other legal or equitable remedies it may have for such breach or proposed breach, the Company shall have the right to terminate or suspend your Severance Benefits. The terms of or
suspension of your Severance Benefits in the event of such a breach or proposed breach by you will not affect your Restrictive Covenant obligations or any other post-employment obligation arising from this letter agreement or otherwise. 

7. You will continue to be employed on an at will basis, meaning your employment may be terminated by you or the Company at anytime and for any
reason, provided that, if your employment is terminated either (1) by the Company for any reason other than for Cause (as defined below) or (2) by you for Good Reason (as defined below), you will be entitled to (a) severance in the
form of a gross lump sum payment equal to your monthly base salary in effect as of the time of such termination multiplied by fifteen (15) and (b) the monthly premium for your continued group health insurance coverage under COBRA for the
lesser of fifteen (15) months or until you are eligible for alternative group health insurance (to the extent you timely elect to continue your group health coverage under COBRA) (collectively, “Severance Benefits”). The Severance
Benefits shall be subject to all applicable federal, state and local payroll and withholding taxes. Our obligation to deliver any Severance Benefits shall be conditioned upon your executing and returning, within the timeframe set forth in the
document that shall not exceed 45 days, a 

 Letter to William K. Heiden 
 Dated December 17, 2007 
 3 of 6 
  

 
separation agreement and general release in a form acceptable to the Company. The Severance Benefits shall commence on the next regular payroll date
following the effective date of the separation agreement. You hereby authorize the Company to offset any definitive amount owed to the Company as of the date of termination from your final pay or Severance Benefits. You shall not be eligible for
Severance Benefits in the event that your employment is terminated (x) by you for reasons other than Good Reason, (y) by the Company for Cause or (z) by reason of your death or Disability (as defined below). 
 For purposes of the preceeding paragraph only, the terms “Cause,” “Good Reason,” and “Disability” shall be defined as
follows. 
 A termination for “Cause” shall mean a termination by the Company for one or more of the following reasons: (i) the
commission by you of a felony, or pleading nolo contendere to a felony, or any other crime or any other violation of law (other than misdemeanors arising out of motor vehicle violations); (ii) your material breach of the terms of this letter
agreement, your Employee Non-Disclosure and Developments Agreement, your Non-Competition and Non-Solicitation Agreement, any other agreement between you and the Company or any of the Company’s policies, including its Insider Trading Policy and
Procedures or Code of Business Conduct and Ethics; (iii) the commission by you of any act of dishonesty, disloyalty, fraud, embezzlement, misappropriation, breach of fiduciary duty or conflict of interest; (iv) the commission by you of any
act that constitutes a violation of the federal or state securities laws; or (v) your continued failure to substantially perform the duties of your position, which remains uncured for the period of thirty calendar days after your receipt of
written notification from the Company of such failure. 
 A termination for “Good Reason” shall mean your resignation from
employment for one or more of the following reasons: (i) the Company’s material breach of the terms of this letter agreement, including the failure of a successor entity to assume the Company’s obligations under this letter agreement;
(ii) a reduction in your base salary, unless such reduction is approved by you or part of a uniform reduction in compensation for all Company executives; (iii) a demotion in your title as President and Chief Executive Officer; (iv) a
substantial diminution in your duties and responsibilities as President and Chief Executive Officer; or (v) the relocation of the Company’s principal corporate office to a location that is 35 miles further than the distance from your home
to the Company’s current location in Cambridge, Massachusetts, without your prior written approval; provided, however, that with respect to each of the conditions described above, you may not establish “Good Reason”
unless you have provided written notice to the Board of the existence of such condition and the Company fails to cure such condition within the thirty day period following receipt of such notice. 
 A “Disability” shall mean any physical incapacity or mental incompetence (x) as a result of which your are unable to substantially perform
your essential duties and responsibilities hereunder for an aggregate of 90 days, whether or not consecutive, in any 180 day period, and (y) which cannot be reasonably accommodated by the Company without undue hardship. 

 Letter to William K. Heiden 
 Dated December 17, 2007 
 4 of 6 
  

 8. Anything in this letter agreement to the contrary notwithstanding, if at the time of your
termination of employment you are considered a “specified employee” within the meaning of Section 409A(a)(2)(B)(i) of the Internal Revenue Code of 1986, as amended (the “Code”), and if any payment that you become entitled to
under this letter agreement would be considered deferred compensation subject to interest and additional tax imposed pursuant to Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, then no
such payment shall be payable prior to the date that is the earlier of (A) six months after your separation from service, or (B) your death, and the initial payment shall include a catch-up amount covering amounts that would otherwise have
been paid during the first six-month period but for the application of this paragraph 8. By signing below, you acknowledge that you and the Company intend that this letter agreement will be administered in accordance with Section 409A of the
Code. By signing below, you acknowledge that you and the Company agree that this letter agreement may be amended, as reasonably requested by either you or the Company as may be necessary to fully comply with Section 409A of the Code and all
related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party. 
 9. In the event that any compensation, payment or distribution by Elixir to or for your benefit, whether paid or payable or distributed or distributable pursuant to the terms of this letter agreement or otherwise (“Severance
Payments”), would be subject to the excise tax imposed by Section 4999 of the Code, then the following provisions shall apply: 
  

	 	A.	If the Severance Payments, reduced by the sum of (1) the Excise Tax and (2) the total of the federal, state, and local income and employment taxes payable by you on the
amount of the Severance Payments which are in excess of the Threshold Amount, are greater than or equal to the Threshold Amount, you shall be entitled to all Severance Payments. 

  

	 	B.	If the Threshold Amount is less than (x) the Severance Payments, but greater than (y) the Severance Payments reduced by the sum of (1) the Excise Tax and (2) the
total of the federal, state, and local income and employment taxes on the amount of the Severance Payments which are in excess of the Threshold Amount, then the benefits payable under this letter agreement shall be reduced (but not below zero) to
the extent necessary so that the maximum Severance Payments shall not exceed the Threshold Amount. 

 Letter to William K. Heiden 
 Dated December 17, 2007 
 5 of 6 
  

 For purposes of this letter agreement, “Threshold Amount” shall mean three times your
“base amount” within the meaning of Section 280G(b)(3) of the Code and the regulations promulgated thereunder less one dollar ($1.00); and “Excise Tax” shall mean the excise tax imposed by Section 4999 of the Code, and
any interest or penalties incurred by you with respect to such excise tax. The determination as to whether the Severance Payments would be subject to the Excise Tax and the calculation of any reduction described above shall be made by a nationally
recognized accounting firm selected by Elixir (the “Accounting Firm”), which shall provide detailed supporting calculations both to Elixir and you within 15 business days of the date of your termination, if applicable, or at such earlier
time as is reasonably requested by Elixir or you. For purposes of such determination, you shall be deemed to pay federal income taxes at the highest marginal rate of federal income taxation applicable to individuals for the calendar year in which
the determination is to be made, and state and local income taxes at the highest marginal rates of individual taxation in the state and locality of you residence on the date of your termination, net of the maximum reduction in federal income taxes
which could be obtained from deduction of such state and local taxes. Any determination by the Accounting Firm shall be binding upon Elixir and you. 
 10. This offer is conditioned on your representation that you were not at the time you joined Elixir, and continue not to be, subject to any confidentiality, noncompetition agreement or any other similar type of
restriction that may affect your ability to devote full time and attention to your work at Elixir. 
 11. Our offer in this letter agreement
and your acceptance thereof are not meant to be a contract of employment for a specific term. This means that, after signing below, you will retain the right to terminate your employment at any time and Elixir will also retain that right, as well as
the right to modify your compensation, job duties and other terms and conditions of your employment. Thus, nothing in this letter agreement affects your status as an at-will employee. 

 In signing this letter agreement you acknowledge and agree that this is the complete agreement between
you and the Company with respect to the subject matter addressed in this letter agreement. You are not relying on any promises or understandings with respect to your employment that are not set forth expressly in this letter agreement, including
without limitation any promises or understandings implied through the course of dealing or otherwise between you and Elixir during your employment through the date hereof. Further, you acknowledge and agree that this letter agreement supersedes all
prior agreements between the parties including the Prior Letter Agreement, except that this letter agreement shall have no effect on any agreement related to any option or other equity award granted to you prior to the effective date of this letter
agreement or on any agreement related to your ethical or conduct obligations. 
 If the terms of this letter agreement are acceptable to you,
please sign and return it to me at your earliest convenience. 
  

			
	Very Truly Yours,
		
	By:	 	/s/ Gregory D. Perry
	Name:	 	Gregory D. Perry
	Title:	 	Chief Financial Officer
	
	Accepted and Agreed.

  

									
	Name:	 	/s/ William K. Heiden	 		 		 	                Date: December 17,2007
		 	William K. Heiden

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00134-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00134-of-00352.parquet"}]]